Cue reported 2024 fiscal-year earnings on Monday after the market closed. Cue Biopharma, Inc. (NASDAQ: CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results